满￥6666，赠豪华版黑神话悟空
Ambeed 大中华区 CN | ZH

中文 - ZH English - EN

Ambeed.cn

搜索

关键字搜索批量搜索

首页 收藏 购物车0
首页 /
抑制剂/激动剂
细胞生物学 药物研究 肿瘤
/
细胞凋亡
动物造模剂 小分子阳性药 DNA损伤 细胞周期 细胞凋亡 其他抑制剂/激动剂 肿瘤表观遗传和基因调控
/
DNA
疼痛和瘙痒模型 抗肿瘤 DNA烷基化剂/交联剂 细胞凋亡诱导剂
/ Oxaliplatin

奥沙利铂 /Oxaliplatin 98%

货号：A100048 同义名： Lipoxal;RP 54780 Ambeed 开学季，买赠积分，赢豪礼

Oxaliplatin inhibits DNA synthesis by conforming DNA adducts.

Oxaliplatin 化学结构 CAS号：61825-94-3
Oxaliplatin 化学结构
CAS号：61825-94-3
Oxaliplatin 3D分子结构
CAS号：61825-94-3
Oxaliplatin 化学结构 CAS号：61825-94-3
Oxaliplatin 3D分子结构 CAS号：61825-94-3
规格 价格 会员价 库存 数量
{[ item.pr_size ]}

{[ getRatePrice(item.pr_rmb, 1,1) ]}

{[ getRatePrice(item.pr_rmb_sale, 1,1) ]}

{[ getRatePrice(item.pr_rmb, 1,1) ]}

{[ getRatePrice(item.pr_rmb,item.pr_rate,1) ]} 		{[ getRatePrice(item.pr_rmb, 1,1) ]} {[ getRatePrice(item.pr_rmb_sale, 1,1) ]} {[ getRatePrice(item.pr_rmb,item.pr_rate,item.mem_rate) ]} {[ getRatePrice(item.pr_rmb,1,item.mem_rate) ]} 现货 咨询 - +
购物车0 收藏 询单

Oxaliplatin 纯度/质量文件 产品仅供科研

货号：A100048 标准纯度： 98%
批次查询： 批次纯度:

全球学术期刊中引用的产品

• Cell,2024. Ambeed. [ A125712 ]
• Cancer Discov., 2024. Ambeed. [ A285925 ]
• JMC, 2024, 67(17): 14974-14985. Ambeed. [ A288696 ]
• JMC, 2024, 67(17): 15061-15079. Ambeed. [ A524399 , A633512 , A144280 , A174613 ]
• EJNMMI Radiopharm. Chem., 2024, 9, 61. Ambeed. [ A1257961 , A622068 ]
更多 >
产品名称 DNA synthesis ↓ helicase ↓ RdRp ↓ ribonucleotide reductase ↓ tRNA synthetase ↓ YB-1 ↓ 其他靶点 纯度
Fexinidazole ✔ 98%
Daptomycin ✔ 98%
Blasticidin S·HCl ✔ 98%
Metronidazole ✔ 98%
Daunorubicin HCl +++

DNA synthesis, Ki: 20 nM

 		98%
Triglycidyl isocyanurate ✔ p53 98+%
Nedaplatin ✔ 99%+
Bendamustine ✔ 98+%
Trifluridine ✔ 98%
Robinetin ✔ 99%+
Carboplatin ✔ 99%
Cidofovir ✔ 99%
Cisplatin ✔ 99%
Cytarabine ++++

DNA synthesis, IC50: 16 nM

 		98%
Acelarin ++++

DNA synthesis, EC50: 0.2 nM

 		99%+
Oxaliplatin ✔ 98%
YK-4-279 ✔ 99%+
ML216 +

BLMfull-length, IC50: 2.98 μM

BLM636-1298, IC50: 0.97 μM

 		99%+
RK-33 ✔ 98%
Brr2-IN-3 ✔ 99%+
Phen-DC3 Trifluoromethanesulfonate ✔ 98%
Favipiravir ✔ 97%
Suramin sodium salt ++

RdRp, IC50: 0.26 μM

 		99%+
Clofarabine ++

Ribonucleotide reductase, IC50: 65 nM

 		97%
Didox ✔ 98%
(E)-3-AP ✔ 97%
Halofuginone +++

prolyl-tRNA synthetase, Ki: 18.3nM

 		99%+
BC-LI-0186 +++

Leucyl-tRNA synthetase, IC50: 46.11 nM

Leucyl-tRNA synthetase, Kd: 42.1 nM

 		98%
SU056 +

YB-1, IC50: 1.73 μM

 		98%
1. 鼠标悬停在“+”上可以显示相关IC50的具体数值。"+"越多，抑制作用越强。2. "✔"表示该化合物对相应的亚型有抑制作用，但抑制强度暂时没有相关数据。

Oxaliplatin 生物活性

靶点

  • DNA synthesis
描述 DNA damage is an abnormal chemical structure in DNA, while a mutation is a change in the sequence of standard base pairs. Oxaliplatin is an alkylating agent that inhibits DNA synthesis and replication by generating DNA damage[1]. Oxaliplatin can induces immunogenic cell death by provoking the presentation of damage associated molecular patterns. Oxaliplatin inhibited human colorectal tumor cell lines HCT-8, HT-29 and HCT 116 with IC50 values of 0.87 μM, 0.88 μM and 0.53 μM, respectively[2]. Oxaliplatin inhibited human bladder cancer cell lines TCC SUP and RT-4 with IC50 values of 15.04 and 11.10 μM, respectively. Oxaliplatin inhibited human Glioma cell lines U-87MG and U-373MG with IC50 values of 17.60 and 2.95 μM, respectively[3]. Furthermore, oxaliplatin could active mTOR pathway via increasing the level of phosphorylated p70 S6 kinase in five ATCC cell lines HCT15, DLD-1, LoVo, HCT116, HT29 and Colo 205[4]. In vivo, administration of 10 mg/kg Oxaliplatin via tail vein injection once a week for 4 weeks significantly inhibited the MHCC97 cells subcutaneously tumor[5]. Treatment with Oxaliplatin at the dose of 10 mg/kg once a week for 4 weeks inhibited the growth of human hepatocellular HCCLM3 xenografts in nude mice[6]. Treatment with oxaliplatin at the dose of 10 mg/kg induced mTOR activation and immunogenic cell death in colon cancer xenografts model. In early clinical, oxaliplatin demonstrated clinical activity in a variety of tumors, including CRC, breast, endometrial cancers and malignant melanoma[7].

Oxaliplatin 细胞研究

细胞系 浓度 检测类型 检测时间 活动说明 数据源
A549 Growth Inhibition Assay IC50=5.8 ± 0.6 μM 25625243
A549 Growth Inhibition Assay IC50=51.08 ± 10.96 μM 25307448
A549/CDDP Growth Inhibition Assay IC50=18.6 ± 1.2 μM 25625243
AGS Growth Inhibition Assay IC50=10.6 μM 25789057

Oxaliplatin 动物研究

Dose Mice: 2 mg/kg, 6 mg/kg[3] (i.p.), 5 mg/kg - 40 mg/kg[4] (i.p.), 3.5 mg/kg[5] (i.v.)
Rat[6] : 2.3 mg/kg - 5 mg/kg (i.v.), 30 mg/kg (p.o.)
Administration i.p., i.v., p.o.

Oxaliplatin 临床研究

NCT号 适应症或疾病 临床期 招募状态 预计完成时间 地点
NCT01157052 Neoplasms, Colorectal ... 展开 >> Colorectal Cancer Colorectal Carcinoma 收起 << Phase 1 Unknown September 2015 Canada, Alberta ... 展开 >> Cross Cancer Institute Not yet recruiting Edmonton, Alberta, Canada, T6G 1Z2 Sub-Investigator: Judith Meza-Junco, MD 收起 <<
NCT00005856 Adult Giant Cell Glioblastoma ... 展开 >> Adult Glioblastoma Adult Gliosarcoma 收起 << Phase 1 Phase 2 Terminated(Administratively co... 展开 >>mplete.) 收起 << - United States, Maryland ... 展开 >> New Approaches to Brain Tumor Therapy Consortium Baltimore, Maryland, United States, 21231-1000 收起 <<
NCT01795027 Gastric Cancer Phase 3 Unknown June 2018 China, Guangdong ... 展开 >> the central hospital of Chaozhou Chaozhou, Guangdong, China the 1st people's hospital of Foshan Foshan, Guangdong, China cancer center of Guangzhou medical college Guangzhou, Guangdong, China cancer center of Sun yat-sen University Guangzhou, Guangdong, China Guangdong Traditional Medical Hospital Guangzhou, Guangdong, China the 1st affliated hospital of Guangdong pharmacuetic college Guangzhou, Guangdong, China the 1St Affliated Hospital of Guangzhou Medical College Guangzhou, Guangdong, China the 6th affliated hospital of Sun-yat-sen University Guangzhou, Guangdong, China the 1st hospital of Shantou University Shantou, Guangdong, China the cental hospital of Shantou Shantou, Guangdong, China YUE-BEI people's hospital Shaoguan, Guangdong, China the 2nd people's hospital of Shenzhen Shenzhen, Guangdong, China the 5th hospital of Sun-yat-sen University Zhuhai, Guangdong, China 收起 <<

Oxaliplatin 参考文献

[1]Arango D, Wilson AJ, Shi Q, Corner GA, Arañes MJ, Nicholas C, Lesser M, Mariadason JM, Augenlicht LH. Molecular mechanisms of action and prediction of response to oxaliplatin in colorectal cancer cells. Br J Cancer. 2004 Nov 29;91(11):1931-46. doi: 10.1038/sj.bjc.6602215. PMID: 15545975; PMCID: PMC2409767.

[2]Balin-Gauthier D, Delord JP, Rochaix P, Mallard V, Thomas F, Hennebelle I, Bugat R, Canal P, Allal C. In vivo and in vitro antitumor activity of oxaliplatin in combination with cetuximab in human colorectal tumor cell lines expressing different level of EGFR. Cancer Chemother Pharmacol. 2006 Jun;57(6):709-18. doi: 10.1007/s00280-005-0123-3. Epub 2005 Dec 1. PMID: 16320055.

[3]Rixe O, Ortuzar W, Alvarez M, Parker R, Reed E, Paull K, Fojo T. Oxaliplatin, tetraplatin, cisplatin, and carboplatin: spectrum of activity in drug-resistant cell lines and in the cell lines of the National Cancer Institute's Anticancer Drug Screen panel. Biochem Pharmacol. 1996 Dec 24;52(12):1855-65. doi: 10.1016/s0006-2952(97)81490-6. PMID: 8951344.

[4]Lu M, Zessin AS, Glover W, Hsu DS. Activation of the mTOR Pathway by Oxaliplatin in the Treatment of Colorectal Cancer Liver Metastasis. PLoS One. 2017 Jan 6;12(1):e0169439. doi: 10.1371/journal.pone.0169439. PMID: 28060954; PMCID: PMC5218497.

[5]Bu Y, Jia QA, Ren ZG, Zhang JB, Jiang XM, Liang L, Xue TC, Zhang QB, Wang YH, Zhang L, Xie XY, Tang ZY. Maintenance of stemness in oxaliplatin-resistant hepatocellular carcinoma is associated with increased autocrine of IGF1. PLoS One. 2014 Mar 14;9(3):e89686. doi: 10.1371/journal.pone.0089686. PMID: 24632571; PMCID: PMC3954560.

[6]Wang Z, Zhou J, Fan J, Qiu SJ, Yu Y, Huang XW, Sun J, Tan CJ, Dai Z. Oxaliplatin induces apoptosis in hepatocellular carcinoma cells and inhibits tumor growth. Expert Opin Investig Drugs. 2009 Nov;18(11):1595-604. doi: 10.1517/13543780903292626. PMID: 19780708.

[7]Misset JL, Bleiberg H, Sutherland W, Bekradda M, Cvitkovic E. Oxaliplatin clinical activity: a review. Crit Rev Oncol Hematol. 2000 Aug;35(2):75-93. doi: 10.1016/s1040-8428(00)00070-6. PMID: 10936465.

Oxaliplatin 实验方案

计算器
存储液制备 1mg 5mg 10mg

1 mM

5 mM

10 mM

2.52mL

0.50mL

0.25mL

12.59mL

2.52mL

1.26mL

25.17mL

5.03mL

2.52mL

Oxaliplatin 技术信息

CAS号61825-94-3
分子式C8H14N2O4Pt
分子量 397.286
别名 Lipoxal;RP 54780;SR96669.;Code names: JM83;LOHP;Abbreviations: 1OHP;Eloxatine;Dacplat;US brand name: Eloxatin Foreign brand names: Dacotin;oxalatoplatinum;oxalatoplatin;diaminocyclohexane oxalatoplatinum;NSC 266046
运输蓝冰
存储条件

粉末 Keep in dark place,Inert atmosphere,Store in freezer, under -20°C

液体 -20°C:3-6个月-80°C:12个月
溶解度

H2O: 2 mg/mL(5.03 mM)，配合低频超声，并水浴加热至45℃助溶

DMF: 1.5 mg/mL(3.78 mM)，配合低频超声助溶
动物实验配方

IP 2% DMSO+water 1 mg/mL clear

PO 0.5% CMC-Na 55 mg/mL suspension

Tags: Oxaliplatin | Lipoxal;RP 54780;SR96669.;Code names: JM83;LOHP;Abbreviations: 1OHP;Eloxatine;Dacplat;US brand name: Eloxatin Foreign brand names: Dacotin;oxalatoplatinum;oxalatoplatin;diaminocyclohexane oxalatoplatinum;NSC 266046 | Apoptosis Inducer | Pain and Pruritus Model | Anti-tumor | DNA/RNA Synthesis | DNA Alkylator/Crosslinker | AmBeed-信号通路专用抑制剂 | Oxaliplatin 纯度/质量文件 | Oxaliplatin 亚型比较 | Oxaliplatin 生物活性 | Oxaliplatin 细胞研究 | Oxaliplatin 动物研究 | Oxaliplatin 临床数据 | Oxaliplatin 参考文献 | Oxaliplatin 实验方案 | Oxaliplatin 技术信息

Ambeed 相关网站 Ambeed.cn Ambeed.com
Ambeed
关于我们
联系我们
资讯中心
网站地图
产品手册
  • 批次文件查询
    • 客户支持
    专业术语
    缩略词释义
    质量手册
    产品咨询
    计算器
    活动政策
    订购方法
    活动声明
    联系我们
    400-920-2911 sales@ambeed.cn tech@ambeed.cn
    Ambeed 只为有资质的科研机构、医药企业基于科学研究或药证申报的用途提供医药研发服务，不为任何个人或者非科研性质用途提供服务。

    尊敬的 Ambeed 客户您好，
    请您选择所在区域，我们将转接对应客服为您服务！

    热门区域

    A

    B

    C

    F

    G

    H

    J

    L

    N

    Q

    S

    T

    X

    Y

    Z

    热 A B C F G H J L N Q S T X Y Z